Rezolute Inc
RZLT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$382.05M
Close$
$0.09
97.6% downside
Current Fair Value
97.6% downsideOvervalued by 97.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $382.05 Million |
|---|---|
| Enterprise Value | $371.44 Million |
| Earnings per Share | $-0.75 |
| Beta | 0.61 |
| Outstanding Shares | 104,488,000 |
Return
| Return on Equity | -77.06% |
|---|---|
| Return on Assets | -68.75% |
| Return on Invested Capital | -31.74% |
Valuation & Multiples
| P/E Ratio | -5.2 |
|---|---|
| PEG | 32.51 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.37 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 24, 2026
EPS Estimate
$-0.15
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.18
Consensus analyst estimateRevenue Estimate
$1.12 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 4.72% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.12%▼ 83.83% |
|---|---|
| Total Invested | $518,108▼ 99.89% |
| Investors Holding | 8▼ 144.00% |
About Rezolute Inc
23 employees
CEO: Nevan Elam
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric endocrine disorder. Its pipeline a...